BRAINTREE, Mass., Oct. 29, 2012 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today reported second quarter 2013 net revenue of $218.2 million, up 22%, GAAP net income of $6.5 million, down 53%, and diluted earnings per share of $0.25, down 53%. Excluding restructuring, transformation, integration and transaction costs, adjusted net income was $23.5 million, up 26%, and adjusted earnings per share were $0.90, up 25%. Organic net revenue, exclusive of the recently acquired whole blood business, was $189.6 million, up 6%. Excluding currency impacts, net revenue was up 22% in total and 6% on an organic basis.[1]
